The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

Conditions

• Severe Periodontitis

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Accepted

Interventions

• Valacyclovir group — DRUG
  The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
• Control group — OTHER
  The control group will receive placebo medication, three times a day for 3 days.

Study Details

The experiment outlined in this proposal is designed to test the hypothesis that herpesvirus suppression by the systemic anti-herpesvirus valacyclovir (Valtrex) can significantly help to arrest the progressive course of severe marginal periodontitis in adult patients. A prospective, randomized, placebo-controlled, double-blind, clinical trial is employed to test this hypothesis.

Key Dates

Start date

May 25, 2023

Status verified

Jul 2023

Primary completion

Mar 1, 2024

Completion

Mar 1, 2024

Study Design

Enrollment

40 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: valacyclovir group
  Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) ("Valacyclovir" group).
• Active Comparator: Control group
  Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days ("Control" group).

Primary Outcome Measure

Clinical attachment level [ Time Frame: 6 months ]

Central Contacts

• Mike Sabeti, DDS
  415-476-0822
  [email protected]

Locations (1)

Find similar trials in San Francisco, CA